Skip to content

Evaluation of Treatment for Leukoderma by Cellular Level Resolution Full-field Optical Coherence Tomography

Evaluation of Treatment for Leukoderma by Cellular Level Resolution Full-field Optical Coherence Tomography

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04935424
Enrollment
65
Registered
2021-06-23
Start date
2021-08-03
Completion date
2022-12-31
Last updated
2023-04-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Leukoderma

Keywords

Optical coherence tomography (OCT), dermatology, Full-Field OCT, Non-invasive image system, Leukoderma

Brief summary

OCT is an optical technology that emerged as a non-invasive skin imaging for the skin. In this protocol, the investigators plan to study the optical imaging features of leukoderma. An estimated 65 subjects will be included in this trial. This is an observational, non-randomised, non-controlled, prospective cohort study to observe the feasibility of in vivo OCT as a image tool in the diagnosis of leukoderma. Use of the device will not affect the clinical management of the subjects. Scientific Aim: To evaluate the feasibility ApolloVue S100 image system as a tool in the differential diagnosis of leukoderma..

Interventions

The device is an in vivo non-invasive optical coherence tomography and will be used to obtain at least 6 medical images of normal and lesional skin, respectively, for both experimental group and control group. The ApolloVue S100 image system is a high resolution OCT imaging system that provide real-time visualization of human skin tissue microstructure. The system provides cellular level, two-dimensional, cross-sectional (B-scan) and en face (E-scan) that can assist clinical diagnosis.The system is also equipped with imaging guiding system that could assist in position scanning skin area.

Sponsors

Apollo Medical Optics, Ltd
CollaboratorINDUSTRY
Chang Gung Memorial Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Age ≧ 20 2. Subject with at least one leukoderma lesion 3. Willing to participate in the trial with informed consent

Exclusion criteria

1. Age \< 20 2. Pregnant woman or woman wishing to be pregnant during the study, or during breastfeeding period 3. The investigators consider inappropriate to participate in the trial. 4. Open wound lesion.

Design outcomes

Primary

MeasureTime frameDescription
To describe characteristic features seen by Full-field Optical Coherence Tomography of leukoderma disorders.6 monthsThe study is a descriptive one. To researche the characteristic images of leukoderma. No formal statistical testing of correlations will be performed. All images will be evaluated as a group. First, the investigator will review the OCT images for each imaging site and will determine the presence/absence of leukoderma. Next, comparing with the leukoderma disorders images to highlight any features that may assist in the OCT evaluation.

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026